30. April 2021 11:33
As the Schwyz company Spiden announced, it has raised 18 million dollars in a financing round. So far, Spiden, founded three years ago and since then led by serial entrepreneur Leo Grünstein, has worked in secret. With this first public message, the medical technology start-up announces that its team has developed a technology platform that analyzes biomarkers and drugs taken in real time. It uses the latest optical technologies and artificial intelligence. It can thus perform spectroscopic measurements of physiological fluids, in particular blood.
Grünstein’s vision is based on the fact that, unlike conventional chemical laboratory tests, its optical technology does not destroy the liquid to be analyzed. One day the blood could be measured continuously using an implant. This would make it possible to live healthier lives, detect diseases earlier and help improve and personalize medical treatments.
“How can it be that people want to fly to Mars,” asks Grünstein, “but we lack an understanding of how our food, our surroundings, the medication we take, our movement and our sleep look like in real time affect our health. “He founded Spiden to improve and extend life with real-time feedback.
The current funding round was led by Ornament Health. “We believe Spiden is building the future of preventive medicine as Spiden’s unique data set will help uncover correlations between lifestyle choices, medication and longevity,” said Ornament CEO Snezhana Gurina as quoted in the press release. The Ornament Health App could be Spiden’s partner for the user interface of his data.
In addition to Ornament, the donors include the Swiss company for sanitary products, Geberit, the start-up investment company btov with a branch in St.Gallen, Daniel Gutenberg and well-known and high-ranking former managers of American and Korean companies. mm